{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:43:24Z","timestamp":1794512604638,"version":"4.9.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","award":["Dana-Farber Cancer Institute Innovation Research Fund"],"award-info":[{"award-number":["Dana-Farber Cancer Institute Innovation Research Fund"]}],"id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006691","name":"Harvard Medical School","doi-asserted-by":"publisher","award":["Blavatnik Therapeutics Challenge Award"],"award-info":[{"award-number":["Blavatnik Therapeutics Challenge Award"]}],"id":[{"id":"10.13039\/100006691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41587-024-02339-4","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T10:03:34Z","timestamp":1722333814000},"page":"948-959","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["A CAR enhancer increases the activity and persistence of CAR T cells"],"prefix":"10.1038","volume":"43","author":[{"given":"Taha","family":"Rakhshandehroo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1234-6856","authenticated-orcid":false,"given":"Shreya R.","family":"Mantri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4197-9338","authenticated-orcid":false,"given":"Heydar","family":"Moravej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin B. V.","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Salehi Farid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Munaretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Regan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radia M. M.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Farkash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Kuhnast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1286-1858","authenticated-orcid":false,"given":"Ali","family":"Nili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2352-6393","authenticated-orcid":false,"given":"Uk-Jae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4800-4700","authenticated-orcid":false,"given":"Harris H.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Berland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6315-5857","authenticated-orcid":false,"given":"Ester","family":"Simkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4272-9492","authenticated-orcid":false,"given":"Safak C.","family":"Uslu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheil","family":"Tavakolpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Rowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Codet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haneyeh","family":"Shahbazian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessika","family":"Baral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Pyrdol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1970-9901","authenticated-orcid":false,"given":"Hadi T.","family":"Nia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1829-302X","authenticated-orcid":false,"given":"Kai W.","family":"Wucherpfennig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Rashidian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"2339_CR1","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J. et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123\u20132138 (2016).","journal-title":"J. Clin. Invest."},{"key":"2339_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","volume":"13","author":"G Roex","year":"2020","unstructured":"Roex, G. et al. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J. Hematol. Oncol. 13, 164 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"2339_CR3","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2339_CR4","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.15252\/emmm.201607485","volume":"9","author":"J Hartmann","year":"2017","unstructured":"Hartmann, J., Sch\u00fc\u00dfler\u2010Lenz, M., Bondanza, A. & Buchholz, C. J. Clinical development of CAR T cells\u2014challenges and opportunities in translating innovative treatment concepts. EMBO Mol. Med. 9, 1183\u20131197 (2017).","journal-title":"EMBO Mol. Med."},{"key":"2339_CR5","doi-asserted-by":"publisher","first-page":"eaaz3223","DOI":"10.1126\/sciadv.aaz3223","volume":"6","author":"SE Lindner","year":"2020","unstructured":"Lindner, S. E., Johnson, S. M., Brown, C. E. & Wang, L. D. Chimeric antigen receptor signaling: functional consequences and design implications. Sci. Adv. 6, eaaz3223 (2020).","journal-title":"Sci. Adv."},{"key":"2339_CR6","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","volume":"19","author":"L Amini","year":"2022","unstructured":"Amini, L. et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat. Rev. Clin. Oncol. 19, 342\u2013355 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2339_CR7","doi-asserted-by":"publisher","first-page":"720571","DOI":"10.3389\/fimmu.2021.720571","volume":"12","author":"H Deng","year":"2021","unstructured":"Deng, H. et al. Efficacy of humanized anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma patients with and without extramedullary disease. Front. Immunol. 12, 720571 (2021).","journal-title":"Front. Immunol."},{"key":"2339_CR8","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 388, 1002\u20131014 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2339_CR9","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3324\/haematol.2020.266841","volume":"108","author":"X Zhou","year":"2022","unstructured":"Zhou, X., Rasche, L., Kort\u00fcm, K. M., Mersi, J. & Einsele, H. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. Haematologica 108, 958\u2013968 (2022).","journal-title":"Haematologica"},{"key":"2339_CR10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389, 335\u2013347 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2339_CR11","doi-asserted-by":"publisher","first-page":"e1049","DOI":"10.1002\/cti2.1049","volume":"8","author":"R Weinkove","year":"2019","unstructured":"Weinkove, R., George, P., Dasyam, N. & McLellan, A. D. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin. Transl. Immunol. 8, e1049 (2019).","journal-title":"Clin. Transl. Immunol."},{"key":"2339_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.539654","volume":"11","author":"Q Dai","year":"2020","unstructured":"Dai, Q. et al. 4-1BB signaling boosts the anti-tumor activity of CD28-incorporated 2nd generation chimeric antigen receptor-modified T cells. Front. Immunol. 11, 539654 (2020).","journal-title":"Front. Immunol."},{"key":"2339_CR13","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner, R. G. et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 10, 702\u2013723 (2020).","journal-title":"Cancer Discov."},{"key":"2339_CR14","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.ymthe.2018.01.022","volume":"26","author":"Z Cheng","year":"2018","unstructured":"Cheng, Z. et al. In vivo expansion and antitumor activity of coinfused CD28- and 4-1BB-engineered CAR-T cells in patients with B cell leukemia. Mol. Ther. 26, 976\u2013985 (2018).","journal-title":"Mol. Ther."},{"key":"2339_CR15","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-18-2559","volume":"25","author":"E Drent","year":"2019","unstructured":"Drent, E. et al. Combined CD28 and 4-1BB costimulation potentiates affinity-tuned chimeric antigen receptor-engineered T cells. Clin. Cancer Res. 25, 4014\u20134025 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2339_CR16","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky, L. et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Invest. 126, 3130\u20133144 (2016).","journal-title":"J. Clin. Invest."},{"key":"2339_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"LJ Rupp","year":"2017","unstructured":"Rupp, L. J. et al. CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci. Rep. 7, 737 (2017).","journal-title":"Sci. Rep."},{"key":"2339_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307\u2013312 (2018).","journal-title":"Nature"},{"key":"2339_CR19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht, J. et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat. Med. 25, 82\u201388 (2019).","journal-title":"Nat. Med."},{"key":"2339_CR20","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","volume":"56","author":"S Agarwal","year":"2023","unstructured":"Agarwal, S. et al. Deletion of the inhibitory co-receptor CTLA4 enhances and invigorates chimeric antigen receptor T cells. Immunity 56, 2388\u20132407 (2023).","journal-title":"Immunity"},{"key":"2339_CR21","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","volume":"20","author":"B Hu","year":"2017","unstructured":"Hu, B. et al. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep. 20, 3025\u20133033 (2017).","journal-title":"Cell Rep."},{"key":"2339_CR22","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","volume":"21","author":"M Chmielewski","year":"2017","unstructured":"Chmielewski, M. & Abken, H. C. A. R. T. Cells releasing IL-18 convert to T-Bethigh FoxO1low effectors that exhibit augmented activity against advanced solid tumors. Cell Rep. 21, 3205\u20133219 (2017).","journal-title":"Cell Rep."},{"key":"2339_CR23","doi-asserted-by":"publisher","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","volume":"113","author":"LV Hurton","year":"2016","unstructured":"Hurton, L. V. et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc. Natl Acad. Sci. USA 113, E7788\u2013E7797 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2339_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.omto.2017.12.003","volume":"8","author":"G Kueberuwa","year":"2018","unstructured":"Kueberuwa, G., Kalaitsidou, M., Cheadle, E., Hawkins, R. E. & Gilham, D. E. CD19 CAR T cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity. Mol. Ther. Oncolytics 8, 41\u201351 (2018).","journal-title":"Mol. Ther. Oncolytics"},{"key":"2339_CR25","first-page":"95","volume":"15","author":"ER Hawkins","year":"2021","unstructured":"Hawkins, E. R., D\u2019Souza, R. R. & Klampatsa, A. Armored CAR T-cells: the next chapter in T-cell cancer immunotherapy. Biologics 15, 95\u2013105 (2021).","journal-title":"Biologics"},{"key":"2339_CR26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","volume":"25","author":"S Mohammed","year":"2017","unstructured":"Mohammed, S. et al. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol. Ther. 25, 249\u2013258 (2017).","journal-title":"Mol. Ther."},{"key":"2339_CR27","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.3389\/fimmu.2019.01691","volume":"10","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. An IL-4\/21 inverted cytokine receptor improving CAR-T cell potency in immunosuppressive solid-tumor microenvironment. Front. Immunol. 10, 1691 (2019).","journal-title":"Front. Immunol."},{"key":"2339_CR28","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1126\/science.aar3246","volume":"359","author":"JT Sockolosky","year":"2018","unstructured":"Sockolosky, J. T. et al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine\u2013receptor complexes. Science 359, 1037\u20131042 (2018).","journal-title":"Science"},{"key":"2339_CR29","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1126\/science.aav8692","volume":"365","author":"L Ma","year":"2019","unstructured":"Ma, L. et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science 365, 162\u2013168 (2019).","journal-title":"Science"},{"key":"2339_CR30","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1126\/science.aay5967","volume":"367","author":"K Reinhard","year":"2020","unstructured":"Reinhard, K. et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science 367, 446\u2013453 (2020).","journal-title":"Science"},{"key":"2339_CR31","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1158\/1078-0432.CCR-19-3354","volume":"26","author":"SN Quayle","year":"2020","unstructured":"Quayle, S. N. et al. CUE-101, a novel E7\u2013pHLA\u2013IL2\u2013Fc fusion protein, enhances tumor antigen-specific T-cell activation for the treatment of HPV16-driven malignancies. Clin. Cancer Res. 26, 1953\u20131964 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2339_CR32","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/eji.201646837","volume":"47","author":"D Cibri\u00e1n","year":"2017","unstructured":"Cibri\u00e1n, D. & S\u00e1nchez-Madrid, F. CD69: from activation marker to metabolic gatekeeper. Eur. J. Immunol. 47, 946\u2013953 (2017).","journal-title":"Eur. J. Immunol."},{"key":"2339_CR33","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.4049\/jimmunol.165.5.2556","volume":"165","author":"A Yu","year":"2000","unstructured":"Yu, A., Olosz, F., Choi, C. Y. & Malek, T. R. Efficient internalization of IL-2 depends on the distal portion of the cytoplasmic tail of the IL-2R common \u03b3-chain and a lymphoid cell environment. J. Immunol. 165, 2556\u20132562 (2000).","journal-title":"J. Immunol."},{"key":"2339_CR34","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali, S. A. et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128, 1688\u20131700 (2016).","journal-title":"Blood"},{"key":"2339_CR35","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen, A. D. et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J. Clin. Invest. 129, 2210\u20132221 (2019).","journal-title":"J. Clin. Invest."},{"key":"2339_CR36","doi-asserted-by":"publisher","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","volume":"38","author":"S Mailankody","year":"2020","unstructured":"Mailankody, S. et al. Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): update of the phase 1\/2 EVOLVE study (NCT03430011). J. Clin. Oncol. 38, 8504 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2339_CR37","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer, J. N. et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J. Clin. Oncol. 35, 1803\u20131813 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2339_CR38","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.ymthe.2018.03.016","volume":"26","author":"EL Smith","year":"2018","unstructured":"Smith, E. L. et al. Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector. Mol. Ther. 26, 1447\u20131456 (2018).","journal-title":"Mol. Ther."},{"key":"2339_CR39","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1158\/1535-7163.MCT-18-1146","volume":"18","author":"M Works","year":"2019","unstructured":"Works, M. et al. Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide. Mol. Cancer Ther. 18, 2246\u20132257 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"2339_CR40","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ymthe.2003.07.002","volume":"8","author":"M Ward","year":"2003","unstructured":"Ward, M. et al. A stable murine-based RD114 retroviral packaging line efficiently transduces human hematopoietic cells. Mol. Ther. 8, 804\u2013812 (2003).","journal-title":"Mol. Ther."},{"key":"2339_CR41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/978-1-4939-6548-9_9","volume":"1514","author":"G Li","year":"2017","unstructured":"Li, G., Park, K. & Davila, M. L. Gammaretroviral production and T cell transduction to genetically retarget primary T cells against cancer. Methods Mol. Biol. 1514, 111\u2013118 (2017).","journal-title":"Methods Mol. Biol."},{"key":"2339_CR42","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1038\/nprot.2013.101","volume":"8","author":"CP Guimaraes","year":"2013","unstructured":"Guimaraes, C. P. et al. Site-specific C-terminal and internal loop labeling of proteins using sortase-mediated reactions. Nat. Protoc. 8, 1787\u20131799 (2013).","journal-title":"Nat. Protoc."}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41587-024-02339-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-024-02339-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-024-02339-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T22:02:17Z","timestamp":1750024937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41587-024-02339-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2339"],"URL":"https:\/\/doi.org\/10.1038\/s41587-024-02339-4","relation":{},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]},"assertion":[{"value":"14 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.R. and M.R. are inventors on a related patent application. M.R. is the scientific founder of Koi Biotherapeutics. C.A.J. serves as a consultant for Kite\/Gilead, Novartis, BMS, Sana, Synthekine, Janssen, Miltenyi, Caribou, Galapagos, ADC Therapeutics, AstraZeneca and Abbvie, and receives research funding from Kite\/Gilead. O.N. receives research support from Takeda and Janssen, participates on advisory boards for Bristol Myers Squibb, Janssen, Sanofi, Takeda and GPCR Therapeutics, and receives honoraria from Pfizer. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}